|
OVERVIEW
A decade ago, it was envisaged that the treatment of hypercholesterolemia and hypertension would eventually eliminate coronary heart disease;
however, that goal has not yet been realized. In 2006, the estimated costs associated with coronary heart disease in the US exceeded $145 billion.
Despite the availability of lipid-lowering agents, cardiovascular disease continues to be one of the leading causes of mortality in the US and
worldwide, owing to a rising incidence of obesity and diabetes, among other factors. These activities will revisit coronary heart disease,
discuss the underlying risks, and present strategies for prevention and treatment.
National Planning Committee
LEARNING OBJECTIVES
At the conclusion of these activities, participants should be able to:
- Recognize the types and levels of lipids that
contribute to increased coronary heart disease risk
- Differentiate the factors that contribute to
residual risk, including HDL-C and TG
- Assess the effect of therapies that focus on
lowering LDL-C versus therapies that are directed toward managing
dyslipidemia as whole (ie, “the lipid triad”) in the form of raising
HDL-C and lowering serum TG through single-agent and/or combination
treatment
- Discuss the role of physicians and other members of the health management team in coordinating patient care and ensuring optimal treatment of dyslipidemia
| |
 |
Striking the Right Balance Activities
| |
| |
Disclosure
It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational
programs. All faculty who affect the content of medical education activities sponsored by The Chatham Institute are required to disclose
to the audience any real or apparent conflict of interest related to the activity. The activity faculty are further required to disclose
discussion of off-label uses in their presentations. Faculty not complying with the disclosure policy are not permitted to participate in
the educational activity.
All program content has been peer reviewed for balance and any potential bias. The conflict of interest resolution process aims to
ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and
delivery of continuing medical education activities for the profession.
Planning Committee Disclosures
Sponsorship and Support
These educational activities are sponsored by The Chatham Institute and supported through an educational grant from Abbott Laboratories.
|